Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial

Rebecca Ryan, Aamirah Mussa, Mandisa Singtaa-Madliki, Joanne Batting, Yusentha Balakrishna, Chelsea Morroni, G Justus Hofmeyr, Rebecca Ryan, Aamirah Mussa, Mandisa Singtaa-Madliki, Joanne Batting, Yusentha Balakrishna, Chelsea Morroni, G Justus Hofmeyr

Abstract

Introduction: Hormonal contraception affects endogenous sex steroid levels. Robust evidence from randomized trials of the relative effects of different contraceptive methods is scarce. We compared the effects of three contraceptive methods on serum estradiol levels using data from women (18-35 years) requesting contraception in the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial.

Methods: Women were randomly allocated to the depot medroxyprogesterone acetate intramuscular (DMPA-IM) injection, copper intrauterine device (IUD) or levonorgestrel (LNG) implant. In this sub-study, stored baseline and 6-month serum samples were analyzed in 401 participants from East London, South Africa (DMPA-IM: 131, IUD: 135 and LNG: 135).

Results: Baseline median (interquartile range, IQR) estradiol levels were similar between the three groups [DMPA-IM 229 (152-455), IUD 235 (168-426) and LNG 216 (153-419 pmol/L)]. At 6-months, median estradiol in the IUD group was unchanged (298 (163-467) pmol/L), whilst levels in the DMPA-IM and implant groups were significantly reduced from baseline. The median estradiol level in the DMPA-IM group [139 (97-193) pmol/L] was significantly lower than in both IUD (p < 0.0001) and implant (p = 0.005) groups; and level in the implant group [156 (112-250) pmol/L] was significantly lower than in the IUD group (p = 0.004).

Conclusions: At 6-months (DMPA-IM nadir), median estradiol with DMPA-IM was 53% lower and with the LNG implant, 48% lower than with the IUD. The greater reduction in estradiol levels with the DMPA-IM injection compared to the LNG implant and IUD has implications for the relative psychological, sexual as well as physiological side-effects of these contraceptive methods.

Echo study registration: ClinicalTrials.gov, identifier: NCT02550067.

Keywords: contraception; copper intrauterine device; depot medroxyprogesterone acetate; estradiol; levonorgestrel implant; randomized trial.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Ryan, Mussa, Singtaa-Madliki, Batting, Balakrishna, Morroni and Hofmeyr.

Figures

Figure 1
Figure 1
CONSORT flow diagram.

References

    1. Hamilton KJ, Hewitt SC, Arao Y, Korach KS. Estrogen hormone biology. Curr Top Dev Biol. (2017) 125:109–46. 10.1016/bs.ctdb.2016.12.005
    1. Ratten LK, Plummer EL, Bradshaw CS, Fairley CK, Murray GL, Garland SM, et al. . The effect of exogenous sex steroids on the vaginal microbiota: a systematic review. Front Cell Infect Microbiol. (2021) 11:732423. 10.3389/fcimb.2021.732423
    1. Kumwenda P, Cottier F, Hendry AC, Kneafsey D, Keevan B, Gallagher H, et al. . Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system. Cell Rep. (2022) 38:110183. 10.1016/j.celrep.2021.110183
    1. He Y, Tang R, Deng J, Cai T, He P, Wu J, et al. . Effects of oestrogen on vulvovaginal candidosis. Mycoses. (2022) 65:4–12. 10.1111/myc.13385
    1. Amiel Castro RT, Ehlert U, Fischer S. Variation in genes and hormones of the hypothalamic-pituitary-ovarian axis in female mood disorders - a systematic review and meta-analysis. Front Neuroendocrinol. (2021) 62:100929. 10.1016/j.yfrne.2021.100929
    1. Morssinkhof MWL, van Wylick DW, Priester-Vink S, van der Werf YD, den Heijer M, van den Heuvel OA, et al. . Associations between sex hormones, sleep problems and depression: a systematic review. Neurosci Biobehav Rev. (2020) 118:669–80. 10.1016/j.neubiorev.2020.08.006
    1. Toren P, Dor J, Rehavi M, Weizman A. Hypothalamic-pituitary-ovarian axis and mood. Biol Psychiatry. (1996) 40:1051–5. 10.1016/0006-3223(95)00369-X
    1. Ju R, Ruan X, Xu X, Yang Y, Cheng J, Zhang L, et al. . Sexual dysfunction in Chinese women at different reproductive stages and the positive effect of hormone replacement therapy in the early postmenopause. Eur J Contracept Reprod Heal care Off J Eur Soc Contracept. (2021) 26:246–54. 10.1080/13625187.2020.1867843
    1. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. (2021) 1–9. 10.1017/S109285292100002X. [Epub ahead of print].
    1. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. Reprod Health. (2016) 13:42. 10.1186/s12978-016-0153-9
    1. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plan Reprod Heal care. (2017) 43:175–80. 10.1136/jfprhc-2016-101607
    1. Moreira IF de A, Bianchini MP, Moreira GRC, Almeida AM, Rezende BA. Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study. BMC Womens Health. (2020) 20:240. 10.1186/s12905-020-01107-1
    1. Andryani ZY, Alkautzar AM, Alza N, Taherong F. Firdayanti, Diarfah AD, et al. The relation of estradiol conditions and usage length to sexual dysfunction in progesterone acetate medroxepo acceptories at Bara-Baraya public health center of Makassar. Gac Sanit. (2021) 35:S475–8. 10.1016/j.gaceta.2021.10.075
    1. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium . HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet (London, England). (2019) 394:303–13. 10.1016/S0140-6736(19)31288-7
    1. Hofmeyr GJ, Morrison CS, Baeten JM, Chipato T, Donnell D, Gichangi P, et al. . Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). Gates open Res. (2018) 1:17. 10.12688/gatesopenres.12775.2
    1. Deese J, Lien Chen P, Gao X, Heffron R, Miller A, Steiner M, et al. . Post-randomization differences in condomless vaginal sex among women randomized to DMPA-IM, copper IUD and levonorgestrel implant in the ECHO trial. In: HIV Research for Prevention 2021(2021).
    1. Achilles SL, Mhlanga FG, Musara P, Poloyac SM, Chirenje ZM, Hillier SL. Misreporting of contraceptive hormone use in clinical research participants. Contraception. (2018) 97:346–53. 10.1016/j.contraception.2017.09.013

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa